FDA Approves Daraxonrasib for Pancreatic Cancer — Survival Nearly Doubled, Cost Is $39,800 a Month
— A new pill for one of the deadliest cancers just got federal approval — and its price tag is making headlines almost as much as its results. The U.S. Food and